Frank David, Contributor

Author's posts

More Covid-19 Testing Is The Answer. But How?

To boost Covid-19 testing capacity, we need to understand the key roadblocks.

A Biotech VC’s Prescription For What Ails Pharma

How can we balance innovation and affordability in prescription drugs? Peter Kolchinsky has some ideas.

How Smart Pharma Can Stop Making Bad R&D Choices

Drug companies need to ditch R&D group-think and embrace tough love from outside experts.

When Biotechs Get Breakthrough Therapy Status, Mr. Market Yawns

Biotechs crow about getting special treatment at FDA — but our data show investors don’t give them much credit.

The Cost-Benefit Revolution Is Far From Over

In his new book, Cass Sunstein explores how to bring analytic rigor to policy decisions.